Does the media prefer IOVA or ODTX?

In the previous week, Iovance Biotherapeutics had 48 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Iovance Biotherapeutics' score of 0.63 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 11 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, TLX or ODTX?

Odyssey Therapeutics has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.53 -$7.12M N/A N/A Odyssey Therapeutics N/A N/A N/A -$6.77 N/A

Is TLX or ODTX more profitable?

Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Odyssey Therapeutics N/A N/A N/A

Does the media prefer TLX or ODTX?

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Telix Pharmaceuticals' score of 0.34 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is ODTX or RLAY more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer ODTX or RLAY?

In the previous week, Relay Therapeutics had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Relay Therapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Relay Therapeutics' score of 0.51 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CELC or ODTX?

Celcuity is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Odyssey Therapeutics N/A N/A N/A -$6.77 N/A

Is CELC or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Odyssey Therapeutics N/A N/A N/A

Does the media prefer CELC or ODTX?

In the previous week, Celcuity had 11 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 12 mentions for Celcuity and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Celcuity's score of 0.22 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ABCL or ODTX?

In the previous week, AbCellera Biologics had 16 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 17 mentions for AbCellera Biologics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat AbCellera Biologics' score of 0.07 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Odyssey Therapeutics (ODTX) Competitors

$20.42 -1.80 (-8.10%)

As of 10/1/2026 04:00 PM Eastern

Compare

ODTX vs. IOVA, TLX, RLAY, CELC, and ABCL

Should you buy Odyssey Therapeutics stock or one of its competitors? Odyssey Therapeutics's main competitors and comparable companies include Iovance Biotherapeutics (IOVA), Telix Pharmaceuticals (TLX), Relay Therapeutics (RLAY), Celcuity (CELC), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Odyssey Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Iovance Biotherapeutics presently has a consensus price target of $12.40, suggesting a potential downside of 12.86%. Odyssey Therapeutics has a consensus price target of $35.75, suggesting a potential upside of 75.07%. Given Odyssey Therapeutics' higher possible upside, analysts plainly believe Odyssey Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Odyssey Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Odyssey Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Odyssey Therapeutics	N/A	N/A	N/A

In the previous week, Iovance Biotherapeutics had 48 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Iovance Biotherapeutics' score of 0.63 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	11 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Odyssey Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.46	-$390.98M	-$0.73	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Summary

Iovance Biotherapeutics beats Odyssey Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Odyssey Therapeutics	N/A	N/A	N/A

Odyssey Therapeutics has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.53	-$7.12M	N/A	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Telix Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 91.23%. Odyssey Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 75.07%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Telix Pharmaceuticals' score of 0.34 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Telix Pharmaceuticals beats Odyssey Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Relay Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Odyssey Therapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Relay Therapeutics	N/A	-42.27%	-38.67%

In the previous week, Relay Therapeutics had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 2 mentions for Relay Therapeutics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Relay Therapeutics' score of 0.51 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Relay Therapeutics	$15.35M	263.97	-$276.48M	-$1.57	N/A

Odyssey Therapeutics presently has a consensus price target of $35.75, indicating a potential upside of 75.07%. Relay Therapeutics has a consensus price target of $25.92, indicating a potential upside of 40.17%. Given Odyssey Therapeutics' higher probable upside, equities research analysts clearly believe Odyssey Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

Relay Therapeutics beats Odyssey Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Celcuity presently has a consensus price target of $154.25, suggesting a potential upside of 105.31%. Odyssey Therapeutics has a consensus price target of $35.75, suggesting a potential upside of 75.07%. Given Celcuity's stronger consensus rating and higher possible upside, research analysts plainly believe Celcuity is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Celcuity had 11 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 12 mentions for Celcuity and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat Celcuity's score of 0.22 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Odyssey Therapeutics' return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Odyssey Therapeutics	N/A	N/A	N/A

Celcuity is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Summary

Celcuity beats Odyssey Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Odyssey Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

In the previous week, AbCellera Biologics had 16 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 17 mentions for AbCellera Biologics and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.79 beat AbCellera Biologics' score of 0.07 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AbCellera Biologics presently has a consensus target price of $13.38, suggesting a potential downside of 3.85%. Odyssey Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 75.07%. Given Odyssey Therapeutics' higher possible upside, analysts clearly believe Odyssey Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Odyssey Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	56.77	-$146.41M	-$0.54	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Odyssey Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. Odyssey Therapeutics' return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Odyssey Therapeutics	N/A	N/A	N/A

Summary

AbCellera Biologics and Odyssey Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Odyssey Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ODTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ODTX vs. The Competition

Export

Metric	Odyssey Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.94B	$7.23B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-3.02	13.45	272.64	25.80
Price / Sales	N/A	1,294.46	607.61	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	N/A	16.20	10.72	6.26
Net Income	N/A	-$22.67M	$3.50B	$360.95M
7 Day Performance	-0.44%	-2.49%	-2.04%	-1.81%
1 Month Performance	-23.29%	-10.35%	-6.44%	-4.03%
1 Year Performance	N/A	21.96%	8.95%	2.18%

Odyssey Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ODTX Odyssey Therapeutics	3.1963 of 5 stars	$20.42 -8.1%	$35.75 +75.1%	N/A	$1.07B	N/A	N/A	100	Positive News
IOVA Iovance Biotherapeutics	1.7334 of 5 stars	$10.25 +2.3%	$9.11 -11.1%	+543.9%	$4.64B	$263.50M	N/A	975	Trending News Analyst Forecast Analyst Revision
TLX Telix Pharmaceuticals	4.5154 of 5 stars	$12.59 +0.6%	$20.40 +62.0%	+5.4%	$4.28B	$803.79M	N/A	1,184	Gap Up
RLAY Relay Therapeutics	2.3391 of 5 stars	$18.84 -1.8%	$25.92 +37.6%	+247.6%	$4.13B	$15.35M	N/A	192	High Trading Volume
CELC Celcuity	2.8692 of 5 stars	$80.61 -5.1%	$154.75 +92.0%	+66.1%	$3.94B	N/A	N/A	155	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ODTX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. IOVA, TLX, RLAY, CELC, and ABCL

How does Odyssey Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Odyssey Therapeutics compare to Relay Therapeutics?

Summary

How does Odyssey Therapeutics compare to Celcuity?

Summary

How does Odyssey Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. IOVA, TLX, RLAY, CELC, and ABCL

How does Odyssey Therapeutics compare to Iovance Biotherapeutics?

Do institutionals and insiders believe in IOVA or ODTX?

Do analysts recommend IOVA or ODTX?

Is IOVA or ODTX more profitable?

Does the media prefer IOVA or ODTX?

Which has higher valuation & earnings, IOVA or ODTX?

Summary

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Is TLX or ODTX more profitable?

Which has preferable earnings and valuation, TLX or ODTX?

Do analysts prefer TLX or ODTX?

Does the media prefer TLX or ODTX?

Summary

How does Odyssey Therapeutics compare to Relay Therapeutics?

Do insiders and institutionals hold more shares of ODTX or RLAY?

Is ODTX or RLAY more profitable?

Does the media prefer ODTX or RLAY?

Which has higher valuation and earnings, ODTX or RLAY?

Do analysts rate ODTX or RLAY?

Summary

How does Odyssey Therapeutics compare to Celcuity?

Do analysts prefer CELC or ODTX?

Do institutionals and insiders have more ownership in CELC or ODTX?

Does the media prefer CELC or ODTX?

Is CELC or ODTX more profitable?

Which has better valuation & earnings, CELC or ODTX?

Summary

How does Odyssey Therapeutics compare to AbCellera Biologics?

Does the media refer more to ABCL or ODTX?

Do institutionals & insiders have more ownership in ABCL or ODTX?

Do analysts rate ABCL or ODTX?

Which has stronger valuation and earnings, ABCL or ODTX?

Is ABCL or ODTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools